August 13, 2017Open Access

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

Key Points

Key points are not available for this paper at this time.

Abstract

National Cancer Institute (3P50CA126752, R01CA131027 and P30CA125123), National Heart, Lung, and Blood Institute (R01HL114564), and Leukemia and Lymphoma Society (LLSTR 6227-08).

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Ramos et al. (Sun,) studied this question.

synapsesocial.com/papers/69d8f54c2c87b79b92d18614 https://doi.org/https://doi.org/10.1172/jci94306

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans2010 · 522 citations
2CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy1995 · 444 citations
3The impact of Hodgkin's disease on the immune system.1990 · 84 citations
4An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.1998 · 95 citations
5Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins2013 · 503 citations

AI에게 질문

Bookmark

View Full Paper